University of Auckland's ESPRESSo Trial Reshapes Early Stroke Rehabilitation Thinking

A groundbreaking clinical trial led by researchers at the University of Auckland has cast new light on the optimal timing and intensity of therapy for stroke survivors. The ESPRESSo study, short for Enhancing Spontaneous Recovery after Stroke, tested whether ramping up hand and arm rehabilitation sessions right after a stroke could accelerate recovery. Contrary to long-held assumptions in the field, the results showed no additional benefits from this intensified approach in the very early stages post-stroke.

Conducted at Auckland City Hospital, the trial involved stroke patients with mild to moderate upper limb impairment. Participants were carefully selected using the PREP2 biomarker algorithm, a tool developed by the University of Auckland's Centre for Brain Research to predict recovery potential. This precise selection process ensured the study focused on those most likely to benefit from upper extremity interventions.

The Burden of Stroke in New Zealand and the Push for Better Recovery

Stroke remains a major health challenge in New Zealand, affecting around 9,000 people annually. It ranks as the second leading cause of death and the primary reason for adult disability. Of those who survive the initial event, approximately 70 percent face long-term impairments, with upper limb dysfunction being particularly common and debilitating. Daily activities like dressing, eating, and writing become arduous, profoundly impacting quality of life.

The country's National Stroke Network and recent service specifications emphasize multidisciplinary rehabilitation, recommending at least 45 minutes of therapy per day per discipline during inpatient stays. Yet, resource constraints and patient fatigue often limit delivery. The ESPRESSo trial emerged from a desire to optimize these limited resources by determining if 'more therapy, earlier' could yield superior outcomes.

Unpacking the ESPRESSo Trial: Design and Methodology

This Phase IIa randomized controlled trial enrolled 64 participants between 2021 and 2024. Patients, averaging 67 years old, began therapy within two weeks of their stroke onset. They were divided into three groups: standard care alone, standard care plus high-dose high-intensity conventional therapy, or standard care plus virtual exploratory movement therapy.

The experimental arms received an additional 90 minutes of daily therapy over 15 weekdays—three weeks total. The virtual therapy used an immersive digital platform where patients guided animated aquatic creatures through exploratory hand and arm movements, promoting high-repetition natural motions. Conventional therapy matched this time with traditional exercises led by therapists.

Outcomes were measured using the Action Research Arm Test (ARAT), a gold standard for upper limb function, at baseline, post-intervention, six weeks, and three months (primary endpoint). Secondary measures included the Box and Block Test and patient-reported satisfaction.

Key Findings: No Boost from Extra Early Therapy

All groups showed substantial spontaneous recovery, with ARAT scores improving by about 20 points across the board at three months. However, the high-intensity groups did not outperform standard care. Patients tolerated the extra sessions well, completing nearly all prescribed time, and rated the virtual therapy as enjoyable and feasible.

Professor Winston Byblow, lead investigator from the University of Auckland's School of Exercise, Sport and Rehabilitation Sciences, noted, “We saw substantial recovery in almost all patients, but without any benefit of having extra therapy.” This suggests the brain's innate biological repair mechanisms drive early gains, rather than added therapy volume.

The trial's biomarker-guided approach strengthened these results, as participants had high predicted recovery potential. Limitations included the single-site design and COVID-era recruitment challenges, but the findings align with emerging evidence questioning ultra-early high-dose paradigms.

Biological Insights into Spontaneous Stroke Recovery

Stroke recovery unfolds in phases: hyperacute (days 1-7), acute (weeks 1-4), subacute (months 1-6), and chronic (beyond 6 months). The ESPRESSo results highlight the dominance of spontaneous recovery in the first phase, driven by neuroplasticity— the brain's ability to reorganize neural pathways.

Mechanisms include resolution of edema (brain swelling), collateral circulation development, and synaptic strengthening in undamaged areas. Studies from the ESPRESSo publication indicate these processes peak early, potentially saturating therapy benefits.

In New Zealand, where Māori and Pacific peoples experience strokes a decade younger than Europeans, understanding these timelines is crucial for equitable care.

Implications for New Zealand's Stroke Services

New Zealand's Stroke Rehabilitation Strategy advocates organized, multidisciplinary care, but implementation varies. The trial underscores the need to prioritize patient readiness over rigid dose targets early on. Overloading fatigued patients risks burnout without gains.

Resource allocation could shift toward later intensive phases, where therapy drives incremental improvements. Digital tools like those in ESPRESSo offer scalable, engaging options, especially in rural areas where therapist shortages persist. The Health Research Council of New Zealand's funding of this work exemplifies public investment in evidence-based innovation.

The Role of Technology and Virtual Reality in Rehab

The virtual platform, developed with international collaborators including MindMaze SA, achieved high compliance through gamification. Patients reported it as fun, contrasting repetitive conventional exercises. This aligns with UoA's broader digital health research.

Future integrations could include AI personalization, adapting difficulty to real-time performance. For New Zealand's dispersed population, tele-rehab expands access, reducing travel burdens for whānau (family).

UoA Centre for Brain Research: A Hub for Innovation

Housed within the University of Auckland, the Centre for Brain Research (CBR) pioneers stroke studies, from epidemiology via Auckland Regional Community Stroke cohorts to neuromodulation trials. Prof Byblow's work builds on PREP2, enhancing precision medicine in rehab.

CBR clinics provide cutting-edge assessments, bridging research and care. This ecosystem trains next-gen neuroscientists, physiotherapists, and occupational therapists.

Expert Views and Broader Perspectives

Byblow emphasized, “Rehabilitation is important, but the timing, dose, and a patient’s capacity to engage... matter more than previously appreciated.” Collaborators from Johns Hopkins and UCLA validate the global relevance.

Stakeholders like Stroke Foundation NZ advocate balanced approaches, integrating therapy with lifestyle interventions. Māori health experts stress culturally responsive models, addressing disparities.

Future Directions: Refining Stroke Rehab Protocols

Upcoming UoA trials explore neuromodulation and pharmacology to augment biology. Personalized dosing via biomarkers promises tailored plans. Policy-wise, updated 2026 service specs may incorporate these insights.

Career opportunities abound in rehab sciences—PhDs, postdocs at CBR, clinical roles in neurorehab. For aspiring researchers, UoA offers scholarships in exercise sciences and neuroscience.

Photo by Peter Burdon on Unsplash

Actionable Insights for Patients, Clinicians, and Policymakers

• Prioritize rest and standard care early; ramp intensity post-spontaneous phase.
• Leverage digital tools for engagement without overload.
• Invest in biomarker screening for targeted interventions.
• Enhance whānau support in holistic recovery.
• Advocate for equitable rural access via telehealth.

This UoA-led discovery pivots stroke care toward biology-informed strategies, promising better resource use and outcomes nationwide.